Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia (Q39100229)

9 September 2017

Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia (English)

1 reference

9 September 2017

1 reference

1 reference

Dario Neri

8

0 references

author name string

Katrin L Gutbrodt

1

1 reference

9 September 2017

Christoph Schliemann

2

1 reference

9 September 2017

Leonardo Giovannoni

3

1 reference

9 September 2017

Katharina Frey

4

1 reference

9 September 2017

Thomas Pabst

5

1 reference

9 September 2017

Wolfram Klapper

6

1 reference

9 September 2017

Wolfgang E Berdel

7

1 reference

9 September 2017

language of work or name

English

0 references

publication date

1 September 2013

1 reference

Science Translational Medicine

9 September 2017

1 reference

9 September 2017

5

1 reference

9 September 2017

201

1 reference

9 September 2017

201ra118

1 reference

Induction of angiogenesis during the transition from hyperplasia to neoplasia

9 September 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Immunocytokines: a novel class of potent armed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

A proteomic approach for the identification of vascular markers of liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Interfering with pH regulation in tumours as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3006221

10.1126/SCITRANSLMED.3006221

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference